Exelixis, Inc.

Symphony Evolution, Inc.

Bristol-Myers Squibb Compnay

The Scripps Research Institute

Exelixus, Inc.

Lynne Canne Bannen

Yong Wang

Wei Xu

John M Nuss

Larry Wayne Mann

Richard George Khoury

Vasu Jammalamadaka

Morrison B Mac

Jason Jevious Parks

Timothy Patrick Forsyth

James William Leahy

Diva Sze-Ming Chan

Lisa Esther Dalrymple

Jeff Z Chen

Grace Mann

Minna Bui

Faming Jiang

Wie Xu

Tai Phat Huynh

Craig Stacy Takeuchi

Morrisson B Mac

Moon Jung Kim

Kin Tso

S David Brown

Erick Wang Co

Donna Tra Le

Raju Mohan

Richard Martin

Tie-Lin Wang

Brenton Todd Flatt

Shumeye Mamo

Patrick C Kearney

Xiao-Hui Gu

Michael Charles Nyman

Charles K Marlowe

Zhaoyang Wen

William Bajjalieh

Zerom Tesfai

Jason H Wu

Amy Lew

Brett Murphy

Jeff Chen

William C Stevens

Matthew A Williams

T G Murali Dhar

Neel Kumar Anand

Elena S Koltun

Tsze Tsang

Kenneth D Rice

Stephen B H Kent

Joerg Bussenius

Tom W Muir

Jack Maung

Ping Huang

Philip E Dawson

Charles M Blazey

Atwood Kim Cheung

Simona Costanzo

Larisa Dubenko

Owen Joseph Bowles

Brian Hugh Ridgway

Amy Lew Tsuhako

Sunghoon Ma

Sergey Epshteyn

Gary Lee Lewis

William C Stevens, Jr

Joan C Sangalang

Xian Shi

Steven Charles Defina

Mohamed Ibrahim

Wei Cheng

Byung Gyu Kim

Rhett Ronald Klein

Steven J Bark

Kevin Luke Schnepp

Joon Won Jeong

Robin Tammie Noguchi

Baili Chen

Maurizio Franzini

Morrison Mac

Justin Salvant

Benjamin Spangler

Andrew Raub

Moon Hwan Kim

Patrick Kearney

Larry W Mann

Erick W Co

Disclosed herein are compounds of Formula (I) which inhibit, regulate and/or modulate tyrosine kinase receptors, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities, compositions containing the compounds, methods of using the compounds to treat kinase-dependent diseases and conditions, and methods for making the compounds.

Compounds for the treatment of kinase-dependent disorders

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

Pyridone compounds and methods of use

Disclosed herein are compounds of Formula (I′). Compounds of Formula (I′) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Disclosed herein are compounds of Formula (I'). Compounds of Formula (I&#x2032;) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Disclosed herein are compounds of Formula I'. Compounds of Formula I&#x2032; inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

C-met modulators and methods of use

Described are RORy modulators of the formula (I), and N-oxides thereof, and pharmaceutically acceptable salts thereof, and solvates and hydrates thereof, wherein R, R, R, R, R, R, R, x, y, L, G, Z, the bond denoted by 'q', the ring system denoted by 'A' and the ring system denoted by &#x201c;B&#x201d; are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORy activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORy activity, for example, autoimmune and/or inflammatory disorders. 

ROR&#x3b3; modulators

c-Met modulators and methods of use

The present invention comprises small molecule inhibitors of phosphatidylinositol 3-kinase (PI3K), which is associated with a number of malignancies such as ovarian cancer, cervical cancer, breast cancer, colon cancer, rectal cancer, and glioblastomas, among others. Accordingly, the compounds of the present invention are useful for treating, preventing, and/or inhibiting these diseases.

Phosphatidylinositol 3-kinase inhibitors and methods of their use

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate, and/or modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

C-met modulators and method of use

c-Met modulators and method of use

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Pyrrole derivatives as pharmaceutical agents

The present invention relates to compounds of the Formula (I) and (II) wherein R, R, R-R, m, n, X-X, and Qare defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. 

Kinase modulators and methods of use

Growing community of inventors

Pacifica, CA, United States of America

Lynne Canne Bannen